Spending on new drug development

Health Economics

Volumn 19, Issue 2, 2010, Pages 130-141

  Adams, Christopher Paul ^a   Brantner, Van Vu ^b  

^a FEDERAL TRADE COMMISSION   (United States)

^b Global Consumer and Small Business Banking   (United States)

Author keywords

Drug development; Pharmaceuticals

Indexed keywords

NEW DRUG;

ARTICLE; DRUG COST; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; RESEARCH; UNITED STATES;

EID: 74749088503     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1454     Document Type: Article

References (10)

1. Abrantes-Metz R, Adams C, Metz A. 2005. Pharmaceutical development phases: a duration analysis. Journal Pharmaceutical Finance, Economics and Policy 14(4): 19-42.
2. Adams C, Brantner V. 2003. New drug development: estimating entry from human clinical trials. FTC Working Paper 262, July 7, 2003.
3. Adams C, Brantner V. 2006. Estimating the cost of new drug development: is it really $802m? Health Affairs March/April: 420-428.
4. Cockburn I, Henderson R. 1996. Scale, scope, and spillovers: determinants of research productivity in the pharmaceutical industry. RAND Journal of Economics 27(1): 32-59.
5. Cockburn I, Henderson R. 2001. Scale and scope in drug development: unpacking the advantages of size in the pharmaceutical research. Journal of Health Economics 20(6): 1033-1057.
6. Danzon P, Epstein A, Nicholson S. 2004. Mergers and Acquisitions in the Pharmaceutical and Biotech Industries, The Wharton School, University of Pennsylvania, November.
7. Danzon P, Nicholson S, Sousa Pereira N. 2005. Productivity in biotech-pharmaceutical R&D: the role of experience and alliances. Journal of Health Economics. 24(2): 317-339.
8. DiMasi J, Hansen R, Grabowski H. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185.
9. DiMasi J, Hansen R, Grabowski H. 2004. R&D costs and returns by therapeutic category. Drug Information Journal 38: 211-223.
10. Light D, Warburton R. 2005. Extraordinary claims require extraordinary evidence. Journal of Health Economics 24: 1030-1033.